New Products

JERUSALEM — Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company's supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.

QNASL, a waterless intranasal corticosteroid spray, is currently available to treat patients 12 years of age and older who show symptoms of seasonal allergic rhinitis and perennial allergic rhinitis, the company notes.

HAUPPAUGE, N.Y. — Red Carpet Manicure nail care brand has announced the launch of “Sweet Indulgence,” a six-shade limited-edition collection of LED nail gel polishes for summer.

The line is available now at RedCarpetManicure.com and will roll out in June at Ulta Beauty Stores and Ulta.com.
 
The pastel palette draws inspiration directly from top designer fashion week shows and includes a range of warm hues like peach and lavender to trace elements of pink and sea foam tones.
 

HINCKLEY, England — Sea-Band recently expanded its line of drug-free nausea products with the introduction of Sea-Band Mama. The niche targeted by the new product is pregnant women experiencing morning sickness. 

The new Sea-Band Mama products include Sea-Band Mama Acupressure Wristbands which use the technique of acupressure to trigger the P6 pressure point, which in turn causes the nervous system to release natural chemicals that quell nausea. And there also is Sea-Band Mama Ginger Lozenges with folic acid.

DUBLIN — Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro.

The prescription medicine is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants. Annual sales for the drug were approximately $97 million, according to Symphony Health Solutions

WHIPPANY, N.J. — Bayer HealthCare on Monday announced that the Food and Drug Administration approved the company's new indication for Bayer's Kogenate FS antihemophilic factor VIII (recombinant) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A.

MIDDLESEX, N.J. — CorePharma on Thursday announced the launch of methylphenidate hydrochloride tablets USP, the generic version of Ritalin from Novartis. Methylphenidate is intended for the treatment of narcolepsy and attention deficit disorders.

The drug is available in 5-,10- and 20-mg strengths. Methylphenidate immediate release tablets had U.S. sales of approximately $243 million as of December 2013, according to IMS Data.

BRIDGEWATER, N.J. — Ajanta Pharma USA on Friday announced the launch of risperidone tablets (0.25-mg, 0.5-mg, 1-mg, 2-mg, 3-mg and 4-mg), the generic version of Risperdal. The drug is used to treat schizophrenia and bipolar disorder.

Sales of branded and generic risperidone totalled approximately $147 million for the 12 months ending March 2014, according to IMS Health.

SUWANEE, Ga. — Enaltus recently announced three new additions to its line of ScarAway scar removal products. 

First is ScarAway Scar Repair Gel, featuring patented Kelo-cote technology, a transparent, self-drying 100%-silicone gel designed to improve the appearance of scars and prevent abnormal and excessive scar formation. The transparent gel offers convenient application for custom scar prevention and treatment that can begin the moment a wound has healed or sutures are removed. ScarAway Scar Repair Gel retails for a suggested $29.99.